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ABSTRACT
Introduction: People with diabetes are at
a higher risk of developing a variety of
medical conditions relative to those without
diabetes, resulting in increased healthcare
costs. Self-monitoring of blood glucose
(SMBG) is accepted as a recommended
element of effective diabetes self-management.
However, little is known about the real-world
frequency and actual expenditures associated
with SMBG, as well as the impact of SMBG costs
relative to the cost of diabetes treatments. The
primary objective is to evaluate the real-world
utilization and costs of SMBG tests in Canada
among insulin-treated diabetes patients during
a 12-month follow-up period.
Methods: A retrospective cohort study was
conducted using the IMS Brogan Inc. Drug
Plan database from July 1, 2006 through June
30, 2010. Total costs during the 12-month
follow-up period were assessed, focusing on
blood glucose (BG) testing strip costs, insulin
therapy costs, and costs associated with oral
antidiabetics medications. All prevalent
patients with two or more prescriptions for
insulin between January 1, 2007 and December
31, 2009 were initially included in the analysis,
the first prescription serving as their index date.
Depending on the insulin type(s) used, patients
were subcategorized into one of four insulin
regimen groups (basal, bolus, premix, or basal–
bolus).
Results: Among an initial sample of patients
with two or more claims for insulin between
January 1, 2007 and December 31, 2009,
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142,551 met the aforementioned inclusion and
exclusion criteria. An overall mean utilization
of pharmacy-based blood glucose testing of
approximately 1,094 strips per person per year
was observed, with an average cost per testing
strip of Canadian $0.79. SMBG treatment costs
for insulin users ($860), specifically those
associated with prescription testing strips,
totaled 41.6% of the average annual pharmacy
costs of diabetes-related prescriptions ($2,068).
Conclusion: This study shows that SMBG
accounts for approximately 40% of the total
diabetes-related pharmacy costs for insulin
users.
Keywords: Blood glucose; Cost; Diabetes;
Insulin; Management; Self-monitoring of
blood glucose; Testing
INTRODUCTION
For both type 1 and type 2 diabetes, an
essential component of ongoing clinical and
self-care management of diabetes is sufficient
and accurate glycemic control, which is critical
in preventing or postponing complications
resulting from diabetes, such as heart disease,
kidney disease, nerve damage, and peripheral
vascular disease [1, 2]. The most common
means for measuring glycemic control is by
monitoring glycated hemoglobin (HbA1c),
which gives an average of the blood glucose
over 3 months. A limitation of this method is
that measuring HbA1c levels does not tell
patients what their blood glucose levels are
on a regular, daily basis. Self-monitoring by
testing for urinary glucose is one method of
checking if blood glucose is high, but the
limitation of this test is that it lacks the proven
accuracy of other methods. A more precise
reading can be captured by blood testing,
which is performed by pricking the skin to
obtain a drop of blood, placing that sample on
a testing strip, and gauging the result with a
discrete meter. This method, called self-
monitoring of blood glucose (SMBG), is quite
flexible and convenient in that it can be done
at various points throughout the day, prior to
or following meals, or before or after physical
activity, allowing patients to be constantly
informed of their insulin levels [2].
SMBG in patients with diabetes who use
insulin may contribute to improved glycemic
control and reduced hypoglycemia by allowing
self-adjustments of insulin dose to be made based
on meter readings. SMBG is recognized as a
core component of effective diabetes self-
management for insulin users throughout the
world by major international organizations such
as the American Diabetes Association (ADA) and
the International Diabetes Federation (IDF) [3–6].
SMBG is recommended by the Canadian
Diabetes Association. The Canadian guidelines,
while stating that the frequency of SMBG should
be determined on an individual level, conclude
that SMBG is an essential part of diabetes
management for patients with type 1 diabetes
and state that the benefits and optimal frequency
are less clear for type 2 [7].
Patient self-management is a key element in
the control of diabetes, and is one of the most
challenging regimens of any chronic illness [8].
People with diabetes are asked to perform
SMBG, manage multiple medications,
maintain foot hygiene, adhere to diet and
meal plans, and engage in exercise programs
[9]. While for some insulin users SMBG is an
important component of diabetes care, it poses
a significant inconvenience/burden on the
patient, in addition to the significant and
well-documented economic costs [10–13].
In Canada, annual diabetes costs in 2006
ranged from a low of Canadian $5.7 million in
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Newfoundland and Labrador to a high of
$109.4 million in Ontario. During that same
year, the typical cost per blood glucose test
strip ranged from $0.72 in Ontario to $0.89 in
Newfoundland and Labrador [13]. As SMBG
has gained acceptance as a key component of
diabetes care around the world for specific
insulin users, other country-specific studies
have addressed cost and utilization [14–18].
Currently, information is sparse regarding the
real-world frequency and actual expenditures
associated with SMBG, as well as the impact of
SMBG costs relative to the cost of insulin-
related therapy. This analysis represents a
novel examination of the real-world
frequency of use and costs associated with
SMBG as a part of insulin-based treatment
costs in Canada.
The primary objective of this analysis is to
evaluate the real-world utilization and costs of
SMBG tests in Canada among insulin-treated
diabetes patients during a 12-month follow-up
period. A secondary objective is to investigate
SMBG-test-related costs as a proportion of total
diabetes-related pharmacy costs.
METHODS
A retrospective database analysis was conducted
using the IMS Brogan Inc. Drug Plan database to
collect information on the real-world utilization
and expenses attributed to SMBG in relation to
a specific insulin regimen, and what the costs
for SMBG specifically are when compared to
other treatment costs.
The IMS Brogan Inc. Drug Plan database, based
in Ottawa, Canada, is comprised of drug claims
paid by a variety of private insurers. The database
collects information on over 10 million
Canadians with more than 100 million
prescriptions annually from the private sector.
About 34% of records come from Ontario, 28%
from Quebec, 29% from Western Canada, and
9%fromAtlanticCanada.Nationally, it is estimated
that this database captures approximately 70% of
private drug plan prescription activity.
There are two provincial drug plans that
provide IMS Brogan with patient-level data,
including insulin-treatment-related costs:
Ontario and Quebec. All cost calculations
consist of the acquisition cost (ingredient cost)
as well as allowable mark-ups, dependent upon
province and public/private plans. Dispensing
fees are not included in the costs.
The Ontario Public Drug Plan (OPDP) covers
approximately 2.5 million active claimants and
pays for 115 million prescriptions annually. The
OPDP claimant population is approximately 66%
seniors (over age 65). About 33% of claimants
receive benefits through social assistance (welfare),
disability, or catastrophic illness programs. All
of these claims are adjudicated online and
transmitted monthly to IMS Brogan under a data
services agreement with the Ontario government.
The Quebec Public Drug Plan, Re´gie de
l’Assurance-Maladie de Que´bec (RAMQ), data
is received directly from the plan administrator
and includes all claims paid by the provincial
plan in Quebec. All of the people of Quebec are
eligible to enroll in this government-based
universal healthcare plan regardless of their
financial situation, although it is intended for
people 65 years of age or older, welfare
recipients, persons without a private
healthcare plan, and children of persons
covered by the public plan. This plan covers
approximately 3.3 million beneficiaries or
2 million active claimants.
Inclusion Criteria
To be selected into the study population, subjects
met each of the following inclusion criteria:
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they had at least two claims for insulin (any
type, see Appendix Table 4) during the period
from January 1, 2007 through December 31,
2009 (the index window or case-selection
window). The date of the first such claim for a
patient during the index window was
considered his/her index date and set the
patient’s insulin therapy subgroup. Patients
were categorized into the following four,
mutually exclusive, specific insulin therapy
groups based on their index prescription:
basal, bolus, premixed, basal–bolus. Basal and
bolus patients were categorized as combination
basal–bolus patients based on the presence of a
second insulin type within 30 days of their
initial (index) prescription.
Patients were continuously enrolled in
their health plan for at least the most recent
6 months preceding their index date (their
pre-index period) through at least 12 months
following their index date (the follow-up
period). The pre-index period was used for
describing baseline characteristics, while the
follow-up period was used for outcomes
measurement. Study patients had to be
persistent with insulin therapy throughout
the 12-month follow-up period. Specifically,
patients were considered persistent if they
did not have a gap exceeding 90 days between
two consecutive insulin claims at any time
during the follow-up period. The patients
also had to have at least one pharmacy
claim for blood glucose testing strips during
the 12-month follow-up period, to ensure
SMBG utilization in the final cohort for
analysis.
The selection of only those patients with
evidence of SMBG testing, as well as the
requirement of a 12-month follow-up period,
were intended to ensure consistency with
previous studies for comparative purposes,
most notably that by Cameron et al. [17].
Exclusion Criteria
Patients were excluded from the study population
if they met any of the following exclusion criteria:
they were aged less than 4 years on their index
date; they had prescriptions for more than one
category of insulin (excluding basal–bolus
combination as described above, see Appendix
Table 4) within the first 30 days immediately
following their index date (including the index
date). Patients who had two different types of
insulin at baseline (with the exception of basal–
bolus combination) werealso excluded, inorder to
avoid incorrectly attributing outcome behaviors
to specific insulin groups (misclassification).
Measurements
Allof the followingmeasureswereprovided for the
overall patient cohort, as well as the four specific
subsets of insulin therapy type (basal, bolus,
premixed, basal–bolus; see Appendix Table 4):
demographic and clinical characteristics, blood
glucose testing frequency and associated costs,
and insulin and oral antidiabetic (OAD)
medications costs (see Appendix Table 5).
Baseline Patient Demographic
and Clinical Characteristics
The following patient demographic
characteristics were measured as of the
patient’s index date or during his/her 6-month
pre-index period, except as noted.
• Gender.
• Age group (4–17, 18–34, 35–54, 55–64, or
C65 years) as of their index date.
• Type of patient, based on his/her insulin
utilization.
• Diabetes type proxy: (1) insulin only (type 1)
or (2) insulin and OADs (type 2). The available
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data elements only allowed for differentiation
based on the presence or absence of OADs.
• Type of payer (private or public).
• Province for private drug plans.
• New or continuing insulin therapy, based on
the presence of any insulin in the pre-index
period.
• Total drug utilization costs for all conditions,
including all patient comorbidities, during
the patient’s 6-month pre-index period, not
including the index date, as a broad severity
measure. For continuing patients, this
measure includes diabetes-related costs.
Of note is that the IMS Brogan dataset does
not contain diagnosis codes. Therefore, the
overall burden of comorbid illnesses was
inferred based on the total cost of claims for
medications unrelated to diabetes.
Blood Glucose Testing
Patients’ frequency of blood glucose testing was
monitored throughout their 12-month post-
index follow-up period through claims for
blood glucose test strips reimbursed by public
or private drug plans. Visits to outpatient clinics
or to laboratory/diagnostic centers for the blood
glucose testing cannot be tracked using IMS
Brogan data, so that utilization was not
captured in this study.
Frequency of blood glucose testing is
classified using descriptive statistics (mean,
standard deviation, and median), and was
stratified by the following variables: (1)
patients’ insulin type, and (2) patients’ payer
type (public or private).
SMBG and Diabetes-Related Pharmacy
Costs
The total costs during the 12-month follow-up
period were assessed, focusing on blood glucose
testing strip costs, insulin therapy costs, and
costs associated with OAD medications.
Cost of test strips and the drug costs were
calculated by multiplying the number of units
dispensed by the unit price. For the private drug
plans, the wholesale price was used as a unit price,
while for the public drug plans, the provincial
formulary price was used as a unit price. The
source of the unit prices is Delta PA. Delta PA is an
online application that provides convenient
access to current and historical drug prices.
Sources of data include wholesale, Association
que´be´coise des pharmaciens proprie´taires (AQPP),
and provincial formularies. All formulary prices
are available on their respective websites.
Specific blood glucose testing costs were
summarized to a total cost, as were costs
specifically related to insulin and OAD therapy.
Statistical Analysis
The study population’s baseline demographic
and clinical characteristics were described using
frequency and percentage distributions for
categorical variables and descriptive statistics
(mean, standard deviation, and median) for
continuous and categorical variables. Pearson’s
v2 test was used for statistical testing of
categorical variables; Wilcoxon’s rank-sum test
was used for statistical testing of continuous
and ordinal variables. All data management
and statistical analyses were completed using
statistical analysis software (SAS Institute Inc.,
Cary, NC, USA; version 9.1.3).
RESULTS
Demographics and Clinical Characteristics
Among 326,838 patients in the database with
at least two claims for insulin between
Diabetes Ther (2012) 3:7 Page 5 of 17
123
January 1, 2007 and December 31, 2009,
142,551 patients from both private and
public payers satisfied all of the inclusion
and exclusion criteria (Fig. 1). Categorization
by initial insulin regimen (based on index
date) resulted in the following insulin-specific
subgroups for analysis: 45,003 on basal
insulin, 15,525 on bolus insulin, 38,553 on
premixed insulin, and 43,470 on basal–bolus
combination insulin.
The largest percentage of patients in the
study group fell in the 65? age category
(42.5%), followed by 35–54 (24.6%), 55–64
(22.0%), and B34 years of age (10.8%,
Table 1). The proportion of women in the
overall cohort was 48.9%, ranging from 47.0%
in the basal insulin group to 50.5% in the
bolus group. The majority of patients in the
study group were from either Ontario (58.4%)
or Quebec (30.5%), the most populous
provinces in the country [19]. A higher
proportion of patients on bolus only were
new to insulin therapy, 60.1%, compared with
patients on basal insulin (59.2%, P\0.0001).
Average total pre-index pharmacy costs ranged
from $1,200 for bolus only to $1,431 for
premixed, with an overall cohort average of
$1,346.
Blood Glucose Testing
The overall mean number of pharmacy-based
blood glucose tests in the 12-month follow-up
period was 1,094 (3.0 tests per day), ranging
from 890 tests in the premixed group to 1,413
in the bolus group (Fig. 2). Patients using
premixed insulin had a significantly lower
mean number of annual blood glucose tests
(890) than did patients on a basal regimen (935,
P\0.0001). Patients on a basal regimen had
significantly lower number of blood glucose
tests than did patients using bolus insulin
(1,413, P\0.0001) and patients on a basal–
bolus regimen (1,324, P\0.0001).
Fig. 1 Patient selection ﬂowchart. mo months, SMBG self-management of blood glucose
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SMBG and Diabetes-Related Pharmacy
Costs
The overall cohort had an average annual
pharmacy cost of $2,068 attributable to insulin
treatments, blood glucose test strips, and OADs.
The average cost for pharmacy-related blood
glucose testing was $860 over the 1-year follow-
up period (Table 2). With an overall mean
utilization of pharmacy-based blood glucose
testing of 1,094 strips per year, the average cost
per testing strip was $0.79. Among patients in
privateandpublicdrugplans, themeanutilization
of pharmacy-based blood glucose testing was
899 and 1,211 strips per year, respectively, while
the average cost per testing strip was $0.82 and
$0.77, respectively. Annual blood glucose
testing costs accounted for 37.7% of total
insulin-related costs for the basal insulin group,
compared with 52.8% for bolus, 41.4% for
premixed, and 41.5% for basal–bolus (Table 3).
Compared with the basal insulin group, the
premixed group had significantly lower average
pharmacy costs over the 1-year period ($1,639 for
premixed, $1,960 for basal, P\0.0001). Both the
bolus-only group ($2,106, P = 0.0001) and the
basal–bolus group ($2,546, P\0.0001) had
significantly higher annual total diabetes-related
pharmacy costs compared to the basal-only group.
Test Strip Utilization
Over the 1-year follow-up period, patients
receiving basal–bolus insulin had 11.6
prescriptions for blood glucose testing strips,
compared with 10.8 prescriptions for the bolus
group, 9.0 for the basal group, and 8.0 for the
premixed group (data not shown).
0 300 600 900 1,200 1,500
All patients (n = 142,551)
Basal insulin patients (n = 45,003)
Premixed insulin patients (n = 38,553)
Basal - bolus insulin patients (n = 43,470)












Fig. 2 Total annual per-patient mean (SD) number of pharmacy-based blood glucose tests in a 12-month period, by index
insulin regimen. BG blood glucose, SD standard deviation
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DISCUSSION
SMBG constituted a large part of the treatment
costs for insulin users, with testing strips
($860) totaling over 40% (41.6%) of the total
diabetes-related pharmacy costs ($2,068),
including insulin prescriptions. While the
total costs of insulin use in a population with
diabetes are well studied, as are the proportion
of total costs associated with insulin, the
economic aspects of SMBG for both payers
and patients are not well understood, and
differentially affect specific insulin subgroups.
Most notably, among bolus insulin users,
SMBG costs are 52.8% of the total diabetes-
related costs ($1,112 of $2,106), possibly
because of a higher use of insulin pumps in
the category.
While this study may be unique in its focus
on SMBG costs relative to diabetes-related costs,
previous studies have measured outcomes with
differing objectives. An economic survey to
evaluate the direct costs among families of
patients with type 1 diabetes found that the
largest economic burden was due to SMBG
expenses, which represented 53% of the total
annual diabetes-related costs [20]. While the
surveillance-based methodology of that study
differs from this study’s approach, the similarity
in the proportion of total costs attributable to
SMBG is noteworthy. A 2010 study that also
used the Canadian-based Brogan claims-level
database found that, among insulin-only users,
daily SMBG strip utilization averaged 2.76 in
the Ontario Public Drug plan and 3.18 in
private plans, similar to this study’s finding of
3.00 strips per patient per day [17]. Another
study using the Norwegian Prescription
Database found that 70% of the study’s
diabetic population practiced SMBG, with an
average of 1.7 strips per day [18]. One percent of
patients used 10 or more strips per day,
accounting for 8% of their total costs. Our
analysis identified higher average strip
utilization per day (3.00 strips) among all
insulin type patients, though ours required a
year of persistent insulin utilization, unlike the
Norwegian analysis.
Limitations
A limitation of this study is that outpatient
care costs, such as those for laboratory and
radiology tests, and inpatient care events (such
as the number and length of hospitalizations)
could not be evaluated using this dataset.
Diabetes-related complications were also not
identified, due to the absence of diagnosis
details within the database. Another limitation
related to the lack of diagnosis codes is that
Table 3 Mean proportional blood glucose test strip, insulin therapy, and OAD costs, by insulin regimen type















SMBG cost/total pharmacy cost (%) 41.6 37.8 41.4 41.5 52.8
Insulin therapy cost/total pharmacy cost 48.6 42.7 49.4 54.4 43.2
OAD cost/total pharmacy cost 9.8 19.5 9.2 4.1 3.9
OAD oral antidiabetics, SMBG self-monitoring of blood glucose
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classification by type of diabetes was not
performed, other than differentiation by the
presence or absence of OADs as a proxy. To the
extent that insulin and OAD utilization is
insufficient to accurately categorize patients
by diabetes type, a degree of misclassification
for the overall cohort as well as insulin-specific
groups may have occurred.
Unique to the regional reimbursement
structure within Canada, estimates of blood
glucose test strip utilization and expenditures
for special drug programs (e.g., the Nova Scotia
Diabetes Assistance Program) were not
included in the analysis. These special drug
programs, however, represent a small
proportion of publicly funded drug plans in
Canada.
As this analysis was limited to an insured
insulin-dependent population in Canada, the
economic impact of SMBG in an uninsured
population, as well as among patients using
OAD medications rather than insulin, cannot
be adequately assessed, and represents a suitable
topic for future studies.
It should also be noted that a subset of
patients in the bolus insulin regimen may have
been using insulin pumps, and adjustments for
pump users were not incorporated into the
analysis. Additionally, to the extent that
patients switch their insulin type during the
follow-up period, a portion of patients in this
study may potentially be misclassified
according to therapy type, though such
behavior is assumed to be nondifferential
across subgroups.
Outpatient blood glucose testing may have
been slightly underestimated as some glucose
tests might have been incorporated into a claim
for a test panel (e.g., comprehensive metabolic
panel) and therefore not captured with codes
for outpatient blood glucose test claims.
Additionally, claims for blood glucose testing
may have been overestimated due to the
exclusion of patients with zero claims. Patients
with zero claims may have been following
guidelines for non-pump single-injection
insulin patients, which suggest SMBG as an
option rather than a requirement.
CONCLUSION
This study shows that SMBG constitutes
over 40% of the diabetes-related pharmacy
costs for insulin users, and as such warrants
further study to recognize the impact on
both patients and healthcare reimbursement
systems.
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APPENDIX
See appendix Table 4, Table 5.
Table 4 Insulin therapy types
Category Product DIN







Novolin GE Ultralente 2024276
Humulin L 646148
Humulin N 1959239, 587737, 2241310
Hypurin NPH 2275864
Iletin II Lente 514535




Insulatard NPH Nordisk 552275
Mixtard Nordisk 552259, 1985957
Novolin GE Lente 2024241
Novolin GE NPH 2024268, 2024225
Novolinset GE NPH 2024403
Premixed insulin (short- and long-acting ﬁxed combination) Humalog Mix 25 2240294, 2240296
Humalog Mix 25 Pen 2240295
Humalog Mix 50 2240297, 2240298, 2240299
Humulin 10/90 1962639, 889113
Humulin 20/80 1962655, 889105
Humulin 30/70 1959212, 795879
Humulin 40/60 889091, 1962647
Humulin 50/50 889121, 1962663




Mixtard 15/85 1985973, 773654
Mixtard 30/70 632694
Mixtard 50/50 1985965, 632678
Novolin 30/70 981052
Novolin GE 10/90 2024292
Novolin GE 20/80 2024306
Novolin GE 30/70 2025248, 2024217
Novolin GE 40/60 2024314
Novolin GE 50/50 2024322
Novolin NPH 1986791, 612197
Novolinset 30/70 650935
Novolinset GE 30/70 2024446
Novomix 30 2265443, 2265435







Humulin R 1959220, 586714
Hypurin 2275872
Iletin II Regular 513644
Iletin Regular 446564
Insulin Sulfated 648094, 1934074
Novolin GE Toronto 2024233
Novolinset 30/70 1927485
Novolinset GE 20/80 2024438
Novolinset GE Toronto 2025256
Novolinset Toronto 1927477, 1927477
Novorapid 2244353, 2244353
Velosulin Human 1986805, 632686
DIN drug identiﬁcation number
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Table 5 Oral antidiabetic medications
Categorya Chemical Name DIN
Alpha glucosidase inhibitors Acarbose 2190893, 2190885
Biguanides Metformin HCl 2334437, 2231389, 2229516, 2239214, 2252945, 2252953,
2230670, 2230671, 2284782, 2242794, 2220628, 314552,
2231058, 2230026, 2230027, 2238827, 2242793, 2343606,
2284790, 2257726, 2268493, 2300451, 2229785, 2167786,
2305062, 2341603, 2341522, 2268507, 2265575, 2099233,
2257734, 2229994, 2242726, 2162849, 2246965, 2265583,
2239081, 2314908, 2339110, 2339129, 2269031, 2269058,
2242931, 2242589, 2233999, 2223562, 2242783, 2246820,
2246821, 2331519, 2331527, 2188902, 2242974, 2230475,
2334445, 2343614, 2350289, 2350300, 2353377, 2353385,
2229656, 2314894, 2045710, 2229517, 2162822, 2246613,
2246614, 2246964, 2148765



















Chlorpropamide 312711, 584932, 12556, 399302, 156728, 377937, 430986,
586773, 24716, 21350, 24708, 12564
Tolbutamide 312762, 1987542, 156663, 431168, 2224798, 2224771, 13889,
21849, 12610, 12602, 1987828
Glyburide 2230036, 2248008, 2147548, 2229596, 2236733, 2228939,
2228920, 2234514, 1913689, 2020742, 2248009, 2020734,
2242096, 2242095, 2236548, 2236543, 1900935, 1900927,
2316544, 2236734, 1913670, 2350459, 720941, 2286157,
2286149, 2226804, 2226812, 1959352, 1959360, 2147521,
2229595, 2230037, 720933, 2350467, 2084341, 2085887,
808733, 808741, 2345854, 2345862, 480304, 480290, 2234513,
1990845, 1990837, 2224569, 1987534, 454753, 1987836,
2224550, 2340771, 1913662, 1913654, 12599, 2340763
Gliclazide 2245247, 2293862, 2238103, 2229519, 2248453, 2287072,
2155850, 2248210, 765996, 2297795, 2356422, 2242987,
2348578, 2336316, 2294400, 2254719
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